Article
Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders.
Melatonin Research Group, Department of Psychiatry, BC Children's Hospital, Vancouver, BC, Canada.
Journal of Pineal Research (impact factor:
5.79).
12/2007;
43(4):351-9.
DOI:10.1111/j.1600-079X.2007.00485.x
pp.351-9
Source: PubMed
-
Citations (0)
- Cited In (2)
-
Article: New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists.
[show abstract] [hide abstract]
ABSTRACT: Hypnotic effects of melatonin and melatoninergic drugs are mediated via MT(1) and MT(2) receptors, especially those in the circadian pacemaker, the suprachiasmatic nucleus, which acts on the hypothalamic sleep switch. Therefore, they differ fundamentally from GABAergic hypnotics. Melatoninergic agonists primarily favor sleep initiation and reset the circadian clock to phases allowing persistent sleep, as required in circadian rhythm sleep disorders. A major obstacle for the use of melatonin to support sleep maintenance in primary insomnia results from its short half-life in the circulation. Solutions to this problem have been sought by developing prolonged-release formulations of the natural hormone, or melatoninergic drugs of longer half-life, such as ramelteon, tasimelteon and agomelatine. With all these drugs, improvements of sleep are statistically demonstrable, but remain limited, especially in primary chronic insomnia, so that GABAergic drugs may be indicated. Melatoninergic agonists do not cause next-day hangover and withdrawal effects, or dependence. They do not induce behavioral changes, as sometimes observed with z-drugs. Despite otherwise good tolerability, the use of melatoninergic drugs in children, adolescents, and during pregnancy has been a matter of concern, and should be avoided in autoimmune diseases and Parkinsonism. Problems and limits of melatoninergic hypnotics are compared.Neuropsychiatric Disease and Treatment 02/2009; 5:341-54. · 1.81 Impact Factor -
Article: Onset and stability of melatonin treatment effect in childhood sleep onset insomnia
[show abstract] [hide abstract]
ABSTRACT: Backgroud and objective: To evaluate onset and stability of melatonin treatment effectSleep Science. 04/2010; 3(1):`16-21.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
additional medications
adverse effects
Adverse reaction
behavior
capture caregivers' impressions
commercially available controlled-release melatonin product
double blind cross-over trial
Hypnotics
long-term melatonin therapy
maintenance difficulties
melatonin
melatonin dose
melatonin therapy
neurodevelopmental disabilities
parental comments
prospective long-term studies
second line
structured telephone interview
sustained-release melatonin
treatment-resistant circadian rhythm